103 related articles for article (PubMed ID: 27188740)
1. Amyloid beta directed antibody for Alzheimer's disease, an evidence based meta-analysis.
Li C; Ma Q; Chen S; Feng J; He Y
Cell Mol Biol (Noisy-le-grand); 2016 Apr; 62(4):83-7. PubMed ID: 27188740
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
3. Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease.
Avgerinos KI; Ferrucci L; Kapogiannis D
Ageing Res Rev; 2021 Jul; 68():101339. PubMed ID: 33831607
[TBL] [Abstract][Full Text] [Related]
4. Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials.
Abushouk AI; Elmaraezy A; Aglan A; Salama R; Fouda S; Fouda R; AlSafadi AM
BMC Neurol; 2017 Apr; 17(1):66. PubMed ID: 28376794
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis.
Jeremic D; Navarro-López JD; Jiménez-Díaz L
Ageing Res Rev; 2023 Sep; 90():102012. PubMed ID: 37423541
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of statins in the treatment of Alzheimer's disease: a meta-analysis of randomized controlled trial.
Xuan K; Zhao T; Qu G; Liu H; Chen X; Sun Y
Neurol Sci; 2020 Jun; 41(6):1391-1404. PubMed ID: 31930449
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of monoclonal antibodies against amyloid-beta
Hao Y; Dong M; Sun Y; Duan X; Niu W
Front Neurol; 2023; 14():1147757. PubMed ID: 37006475
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of anti-Aβ agents for delaying cognitive decline in Alzheimer's disease: a meta-analysis.
Li J; Wu X; Tan X; Wang S; Qu R; Wu X; Chen Z; Wang Z; Chen G
Front Aging Neurosci; 2023; 15():1257973. PubMed ID: 38020763
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Penninkilampi R; Brothers HM; Eslick GD
J Neuroimmune Pharmacol; 2017 Mar; 12(1):194-203. PubMed ID: 28025724
[TBL] [Abstract][Full Text] [Related]
10. Effects of three kinds of anti-amyloid-β drugs on clinical, biomarker, neuroimaging outcomes and safety indexes: A systematic review and meta-analysis of phase II/III clinical trials in Alzheimer's disease.
Lyu D; Lyu X; Huang L; Fang B
Ageing Res Rev; 2023 Jul; 88():101959. PubMed ID: 37217078
[TBL] [Abstract][Full Text] [Related]
11. Non-steroidal anti-inflammatory drugs as a treatment for Alzheimer's disease: a systematic review and meta-analysis of treatment effect.
Miguel-Álvarez M; Santos-Lozano A; Sanchis-Gomar F; Fiuza-Luces C; Pareja-Galeano H; Garatachea N; Lucia A
Drugs Aging; 2015 Feb; 32(2):139-47. PubMed ID: 25644018
[TBL] [Abstract][Full Text] [Related]
12. Herbal medicine Davaie Loban in mild to moderate Alzheimer's disease: A 12-week randomized double-blind placebo-controlled clinical trial.
Tajadini H; Saifadini R; Choopani R; Mehrabani M; Kamalinejad M; Haghdoost AA
Complement Ther Med; 2015 Dec; 23(6):767-72. PubMed ID: 26645514
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of anti-amyloid-ß monoclonal antibody therapy in early Alzheimer's disease: a systematic review and meta-analysis.
Dantas JM; Mutarelli A; Navalha DDP; Dagostin CS; Romeiro PHCL; Felix N; Nogueira A; Batista S; Teixeira L; Caramelli P
Neurol Sci; 2024 Jun; 45(6):2461-2469. PubMed ID: 37978096
[TBL] [Abstract][Full Text] [Related]
14. Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.
Yang G; Wang Y; Tian J; Liu JP
PLoS One; 2013; 8(9):e74916. PubMed ID: 24086396
[TBL] [Abstract][Full Text] [Related]
15. Evolution of blood pressure in patients with Alzheimer's disease: a one year survey of a French Cohort (REAL.FR).
Hanon O; Latour F; Seux ML; Lenoir H; Forette F; Rigaud AS;
J Nutr Health Aging; 2005; 9(2):106-11. PubMed ID: 15791354
[TBL] [Abstract][Full Text] [Related]
16. Differences in Alzheimer disease clinical trial outcomes based on age of the participants.
Schneider LS; Kennedy RE; Wang G; Cutter GR
Neurology; 2015 Mar; 84(11):1121-7. PubMed ID: 25681452
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.
Qiao Y; Chi Y; Zhang Q; Ma Y
Front Aging Neurosci; 2023; 15():1169499. PubMed ID: 37213538
[TBL] [Abstract][Full Text] [Related]
18. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
[TBL] [Abstract][Full Text] [Related]
19. Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis.
Lu L; Zheng X; Wang S; Tang C; Zhang Y; Yao G; Zeng J; Ge S; Wen H; Xu M; Guyatt G; Xu N
J Neurol Neurosurg Psychiatry; 2020 Dec; 91(12):1316-1324. PubMed ID: 33046560
[TBL] [Abstract][Full Text] [Related]
20. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
Doody RS; Thomas RG; Farlow M; Iwatsubo T; Vellas B; Joffe S; Kieburtz K; Raman R; Sun X; Aisen PS; Siemers E; Liu-Seifert H; Mohs R; ;
N Engl J Med; 2014 Jan; 370(4):311-21. PubMed ID: 24450890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
